Advertisement

Search Results

Advertisement



Your search for Matthew Stenger matches 212 pages

Showing 101 - 150


prostate cancer

Similar 10-Year Survival Reported With Active Monitoring, Surgery, or Radiotherapy for PSA-Detected Localized Prostate Cancer

In a UK trial (ProtecT) reported in The New England Journal of Medicine, Hamdy et al found no significant differences in prostate cancer–specific or overall mortality among men with localized prostate cancer detected by prostate-specific antigen (PSA) testing who underwent active monitoring,...

prostate cancer

PSA Failure Seems to Be Linked to Poorer Survival in Men With Unfavorable-Risk Prostate Cancer and No/Minimal Comorbidity

In an analysis of a clinical trial population reported in the Journal of Clinical Oncology, Giacalone et al found that prostate-specific antigen (PSA) failure was associated with an increased risk of mortality among men with unfavorable-risk prostate cancer who had no or minimal comorbidity burden. ...

prostate cancer

Continuation of Docetaxel May Improve Survival in Metastatic Castration-Resistant Prostate Cancer

The number of docetaxel cycles completed was associated with improved overall survival among men with metastatic castration-resistant prostate cancer receiving docetaxel, prednisone, and lenalidomide (Revlimid; DPL) or docetaxel/prednisone (DP), in the phase III Mainsail trial. de Morrée et...

prostate cancer

Early-Stage Prostate Cancer Incidence Rates Decline, Distant-Stage Disease Rates Unchanged in 2013

Jemal et al described findings indicating a continued decline in the incidence of localized/regional-stage prostate cancer at 2 years after the U.S. Preventive Services Task Force recommendation against routine prostate-specific antigen (PSA) screening in men aged ≥ 50 years in 2011, in a letter ...

prostate cancer

HSD3B1 Allele May Be Associated With Resistance to Androgen-Deprivation Therapy and Poorer Outcome in Prostate Cancer

In a retrospective multicohort study reported in The Lancet Oncology, Hearn et al found that the inherited HSD3B1 (1245C) allele was significantly associated with resistance to androgen-deprivation therapy and poorer outcome in men with prostate cancer. HSD3B1 (1245A>C) has been linked to...

prostate cancer

Combining Radium-223 With Other Therapies May Be of Benefit in Metastatic Castration-Resistant Prostate Cancer

In an international, single-arm phase IIIB trial reported in The Lancet Oncology, Saad et al found benefit with the addition of abiraterone (Zytiga) or enzalutamide (Xtandi) to radium-223 (Xofigo) in patients with metastatic castration-resistant prostate cancer. This early-access program was...

prostate cancer

Hypofractionated Radiotherapy Not Inferior to Conventional Radiotherapy in Low-Risk Prostate Cancer

In a phase III noninferiority trial (NRG Oncology RTOG 0415) reported by Lee et al in the Journal of Clinical Oncology, W. Robert Lee, MD, MS, Med, of Duke University Medical Center, and colleagues found that hypofractionated radiotherapy was not inferior to conventional hypofractionated...

solid tumors
prostate cancer

No Survival Benefit for Cabozantinib Reported in Previously Treated Metastatic Castration-Resistant Prostate Cancer

Smith et al found no improvement in overall survival with cabozantinib (Cometriq) vs prednisone in patients with previously treated metastatic castration-resistant prostate cancer, in the phase III COMET-1 trial reported in the Journal of Clinical Oncology. Cabozantinib, which inhibits MET, VEGF...

prostate cancer

Mixed Results With Hypofractionated vs Conventional Radiotherapy for Localized Prostate Cancer

Investigators of two European phase III trials have reached different conclusions on whether hypofractionated radiotherapy should replace conventional radiotherapy as a new standard of treatment in localized prostate cancer. The CHHiP trial findings favoring hypofractionation were reported by David ...

prostate cancer

Improved Survival Reported With Prostate Radiation Therapy Plus Androgen-Deprivation Therapy in Metastatic Prostate Cancer

The addition of prostate external-beam radiation therapy to androgen-deprivation therapy was associated with prolonged overall survival in men with newly diagnosed metastatic prostate cancer, according to a National Cancer Database analysis reported by Rusthoven et al in the Journal of Clinical...

prostate cancer

Tasquinimod Improves Radiographic PFS but Not OS in Metastatic Castration-Resistant Prostate Cancer

In a phase III trial reported in the Journal of Clinical Oncology, Sternberg et al found that tasquinimod, an oral therapy targeting components of the tumor microenvironment, increased radiographic progression-free survival but not overall survival vs placebo in men with chemotherapy-naive...

prostate cancer

French Trial Shows Benefit of Adding Short-Term Hormone Therapy to Salvage Radiotherapy for Rising PSA After Prostatectomy

In the phase III GETUG-AFU 16 trial reported in The Lancet Oncology, Carrie et al found that adding short-term androgen suppression therapy to salvage radiotherapy was associated with improved biochemical or clinical progression-free survival among patients with prostate cancer who exhibited rising ...

prostate cancer

Hypofractionated Radiotherapy Not Inferior to Conventional Radiotherapy in Low-Risk Prostate Cancer

Hypofractionated radiotherapy was not inferior to conventional radiotherapy in terms of disease-free survival among men with low-risk prostate cancer, according to the results of the phase III NRG Oncology RTOG 0415 trial reported in the Journal of Clinical Oncology by Lee et al. However, it was...

prostate cancer

Adding 6 Months of Androgen Suppression to Radiotherapy Improves Disease-Free Survival in Intermediate- and High-Risk Prostate Cancer

In the phase III EORTC 22991 trial reported in the Journal of Clinical Oncology, Bolla et al found that the addition of 6 months of androgen suppression to radiotherapy improved biochemical and clinical disease-free survival in patients with intermediate- and high-risk prostate cancer. Study...

prostate cancer

Lower Vitamin D Levels Associated With Adverse Pathology at Prostatectomy in Men With Localized Prostate Cancer

In a study reported in the Journal of Clinical Oncology, Nyame et al found that lower serum 25-hydroxyvitamin D (25-OH D) levels were associated with an increased likelihood of adverse pathology at radical prostatectomy in men with localized prostate cancer. Study Details The cross-sectional...

solid tumors
prostate cancer

Survival Differs With Metastatic Site in Castration-Resistant Prostate Cancer

Overall survival differed according to the site of metastases in men with castration-resistant prostate cancer, according to a meta-analysis reported in the Journal of Clinical Oncology by Halabi et al. Study Details The study involved data from 8,820 men who received docetaxel chemotherapy in...

prostate cancer

Enzalutamide Improves Progression-Free Survival vs Bicalutamide in Nonmetastatic and Metastatic Castration-Resistant Prostate Cancer

Treatment with enzalutamide (Xtandi) tripled median progression-free survival vs bicalutamide in patients with nonmetastatic or metastatic castration-resistant prostate cancer, according to the phase II STRIVE trial reported in the Journal of Clinical Oncology by Penson et al. Study Details In...

prostate cancer

Hypofractionated Radiotherapy Not Noninferior to Standard Radiotherapy in Late Genitourinary and Gastrointestinal Toxicity in Prostate Cancer

Hypofractionated radiotherapy was not noninferior to conventionally fractionated radiotherapy in late genitourinary and gastrointestinal toxicity in patients with prostate cancer in the Dutch phase III HYPRO trial. These findings were reported by Aluwini et al in The Lancet Oncology. An earlier...

prostate cancer

ASCO Endorses Cancer Care Ontario Guideline on Active Surveillance for Management of Localized Prostate Cancer

As reported by Ronald C. Chen, MD, MPH, of the University of North Carolina at Chapel Hill, and colleagues in the Journal of Clinical Oncology, ASCO has endorsed, with qualifications, the 2015 Cancer Care Ontario (CCO) guideline on active surveillance for management of localized prostate cancer....

prostate cancer

Study Finds Enzalutamide Increases Progression-Free Survival vs Bicalutamide in Metastatic Prostate Cancer

Use of the androgen receptor–inhibitor enzalutamide (Xtandi) more than doubled progression-free survival vs the nonsteroidal antiandrogen bicalutamide in patients with metastatic prostate cancer progressing on androgen-deprivation therapy, according to the randomized phase II TERRAIN trial...

solid tumors
prostate cancer

Increased Survival and Toxicity With Docetaxel, No Apparent Benefit of Zoledronic Acid in Prostate Cancer

As reported in The Lancet by James et al, results of the STAMPEDE trial, which used a multiarm, multistage seamless phase II/III design, showed increased survival and toxicity with docetaxel and little benefit of zoledronic acid when added to first-line long-term hormone therapy in patients with...

prostate cancer

Study Finds Association Between Androgen-Deprivation Therapy in Prostate Cancer and Risk of Alzheimer’s Disease

In a retrospective analysis reported in the Journal of Clinical Oncology, Nead et al found that use of androgen-deprivation therapy in the treatment of prostate cancer was associated with an increased risk of subsequent Alzheimer’s disease. Study Details In the study, a text-processing...

prostate cancer

DNA Damage and Repair Pathway Signature May Be Associated With Prognosis After Prostatectomy in High-Risk Prostate Cancer

In a study reported in JAMA Oncology, Evans et al identified a DNA damage and repair pathway gene signature that was significantly associated with outcomes after prostatectomy for high-risk prostate cancer independent of standard clinicopathologic factors. Study Details The study involved 1,090...

prostate cancer
issues in oncology

Swedish Screening Model Improves Performance of Prostate Cancer Screening vs PSA Alone in Men Aged 50–69 Years

In a Swedish study reported in The Lancet Oncology (Stockholm 3 study), Grönberg et al found that a screening model including prostate-specific antigen (PSA) and other plasma protein markers, genetic polymorphisms, and clinical variables improved the accuracy of detecting prostate cancer with...

issues in oncology
prostate cancer
issues in oncology

Decreased Prostate-Specific Antigen Screening and Rate of Diagnosis in Early-Stage Prostate Cancer

Recent data indicated that the rates of prostate-specific antigen (PSA) screening and diagnosis of early-stage prostate cancer have decreased since a 2012 U.S. Preventive Services Task Force (USPSTF) statement (released in October 2011) gave a grade D recommendation against PSA screening for all...

prostate cancer
issues in oncology

Meta-Analysis Indicates Noninferiority of Overall Survival With Intermittent vs Continuous Androgen-Deprivation Therapy in Prostate Cancer

In a meta-analysis reported in JAMA Oncology, Magnan et al found that intermittent androgen-deprivation therapy was noninferior to continuous androgen-deprivation therapy with respect to overall survival in patients with prostate cancer. Study Details A literature review identified 22 articles...

prostate cancer

PARP Inhibitor Olaparib Produces High Response Rate in Metastatic Prostate Cancer With DNA Repair Defects

In a phase II trial reported in The New England Journal of Medicine, Mateo et al found that the PARP inhibitor olaparib (Lynparza) produced a high response rate in patients with previously treated metastatic castration-resistant prostate cancer with tumors exhibiting defects in DNA repair genes....

prostate cancer
supportive care

Similar Pain Outcome With Ibandronate vs Single-Dose Radiotherapy for Localized Metastatic Bone Pain in Prostate Cancer

In a UK phase III noninferiority trial reported in the Journal of the National Cancer Institute, Hoskin et al found similar effects of single-dose ibandronate and single-dose radiotherapy on localized metastatic bone pain in patients with prostate cancer. Study Details In the open-label trial,...

prostate cancer

Active Surveillance Program Improves Intermediate/Longer-Term Outcomes in Favorable-Risk Prostate Cancer

As reported in the Journal of Clinical Oncology by Tosoian et al, a prospective active surveillance program resulted in good intermediate/longer-term outcomes in men with favorable-risk prostate cancer. Study Details The program included 1,298 men with very-low-risk or low-risk disease enrolled...

prostate cancer

Addition of Docetaxel to Androgen-Deprivation Therapy Improves Survival in Metastatic Prostate Cancer

In the phase III E3805 trial reported in The New England Journal of Medicine, Sweeney et al found that chemohormonal therapy with docetaxel plus androgen-deprivation therapy produced a significant 13.6-month increase in median overall survival vs androgen-deprivation therapy alone in men with...

issues in oncology
prostate cancer

Biomarker Signature May Predict Aggressive Disease in African American Men With Prostate Cancer

In a study reported in Journal of Clinical Oncology, Yamoah et al identified a biomarker signature that may predict aggressive disease in African American men with prostate cancer. Study Details In the study, distribution of mRNA expression levels of 20 biomarkers associated with prostate cancer...

solid tumors
pancreatic cancer
prostate cancer
bladder cancer

Analysis Suggests Use of Pioglitazone for Diabetes May Increase Risk of Prostate and Pancreatic Cancers But Not Bladder Cancer

Available data suggest an increased risk of bladder cancer with pioglitazone treatment for diabetes. In an analysis of Kaiser Permanente Northern California data reported in JAMA, Lewis et al found no significantly increased risk of bladder cancer in patients with diabetes ever using pioglitazone....

prostate cancer

Dose-Escalated EBRT Yields Survival Benefit in Intermediate- and High-Risk but Not Low-Risk Nonmetastatic Prostate Cancer

In a retrospective study reported in JAMA Oncology, Kalbasi et al found that dose-escalated external-beam radiation therapy was associated with improved overall survival among men with intermediate- and high-risk, but not low-risk, nonmetastatic prostate cancer. Study Details The study involved...

prostate cancer

Statin Use at Start of Androgen-Deprivation Therapy Increases Time to Progression During Androgen-Deprivation Therapy in Prostate Cancer

Statin use has been associated with improved outcome in prostate cancer. In a study reported in JAMA Oncology, Harshman et al found that statin use at the time of initiation of androgen-deprivation therapy was associated with prolonged time to progression during androgen-deprivation therapy in men...

prostate cancer
issues in oncology

Transient Adverse Quality-of-Life Impact of Radiotherapy Added to Androgen-Deprivation Therapy in Locally Advanced Prostate Cancer

In a study reported in the Journal of Clinical Oncology, Brundage et al found that the addition of radiotherapy to androgen-deprivation therapy in patients with locally advanced prostate cancer in the NCIC CTG PR3/MRC PR07 trial had a transient negative impact on health-related quality of life over ...

prostate cancer

National Cancer Data Base Analysis Indicates Survival Benefit of Adding Radiotherapy to ADT in Clinically Node-Positive Prostate Cancer

In an analysis reported in the Journal of the National Cancer Institute, Lin et al found that the addition of radiotherapy to androgen-deprivation therapy was associated with a significant improvement in overall survival in patients with clinically node-positive prostate cancer. Study Details The ...

issues in oncology
prostate cancer
issues in oncology
issues in oncology

Whole-Exome Sequencing Identifies Biologically Informative Alterations in the Majority of Metastatic Cancers

In a study reported in JAMA Oncology, Beltran et al found that whole-exome sequencing of metastatic and treatment-resistant cancers revealed biologically informative alterations in the majority of cases. Although treatment recommendations could be made in the majority of cases, treatment was guided ...

prostate cancer

French Trial Shows Addition of Docetaxel and Estramustine to ADT Improves Relapse-Free Survival in High-Risk Localized Prostate Cancer

In a French phase III trial (GETUG 12) reported in The Lancet Oncology, Fizazi et al found that the addition of docetaxel and estramustine (Emcyt) to androgen-deprivation therapy (ADT) improved relapse-free survival among patients with high-risk localized prostate cancer. Study Details In the...

prostate cancer

Obesity Poses Greater Prostate Cancer Risk for African American vs White Men

In an analysis of participants in the SELECT prevention trial reported in JAMA Oncology, Barrington et al found that obesity in African American men was associated with a greater risk of prostate cancer than in white men. African American men have the highest prostate cancer incidence and mortality ...

prostate cancer
issues in oncology

Enzalutamide Improves Patient-Reported Outcomes and Time to Skeletal-Related Event vs Placebo in PREVAIL Trial

The PREVAIL trial showed that enzalutamide (Xtandi) improved overall survival and progression-free survival vs placebo in asymptomatic/minimally symptomatic chemotherapy-naive patients with metastatic castration-resistant prostate cancer. In analyses reported in The Lancet Oncology, Loriot et al...

prostate cancer

No Improvement in Undetectable PSA Rate With Cixutumumab Plus Androgen-Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer

In a randomized phase II trial (SWOG S0925) reported in the Journal of Clinical Oncology, Yu et al found that the addition of cixutumumab to androgen-deprivation therapy did not significantly increase the rate of undetectable prostate-specific antigen (PSA) in patients with newly diagnosed...

prostate cancer

Circulating Tumor Cell Count and LDH Level as Patient-Level Surrogate for Survival in Metastatic Castration-Resistant Prostate Cancer

In an analysis reported in the Journal of Clinical Oncology, Scher et al found that circulating tumor cell count and LDH level served as an individual-level surrogate for survival among patients with metastatic castration-resistant prostate cancer receiving abiraterone acetate (Zytiga) plus...

breast cancer
prostate cancer

Regional-Level Correlation of Inappropriate Prostate Imaging and Inappropriate Breast Imaging

In a study reported in JAMA Oncology, Makarov et al found that hospital referral regions marked by higher rates of inappropriate imaging in patients with low-risk breast cancer also had high rates of inappropriate prostate imaging in patients with low-risk prostate cancer. Inappropriate imaging...

prostate cancer

Gonadotropin-Releasing Hormone Agonist Treatment and Orchiectomy Linked to Increased Risk of Cardiovascular Disease in Men With Prostate Cancer

In a study of Swedish men with prostate cancer reported in the Journal of Clinical Oncology, O’Farrell et al found that use of gonadotropin-releasing hormone (GnRH) agonists and orchiectomy were associated with a significantly increased risk of incident cardiovascular disease. In patients...

prostate cancer

Low Nadir Testosterone in First Year of Hormone Therapy Linked to Improved Cause-Specific Survival and Delay of Hormone Resistance in Prostate Cancer

In an analysis from the PR-7 trial reported in the Journal of Clinical Oncology, Klotz et al found that in men with prostate cancer with biochemical failure after radiotherapy with or without surgery, a nadir serum testosterone level ≤ 0.7 nmol/L during the first year of continuous...

prostate cancer

Addition of Lenalidomide to Docetaxel-Prednisone Worsens Survival in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer

In the phase III MAINSAIL trial reported in The Lancet Oncology, Petrylak et al found that the addition of lenalidomide (Revlimid) to docetaxel-prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer was associated with significantly worse overall survival. The...

prostate cancer

Addition of Orteronel to Prednisone in Metastatic Castration-Resistant Prostate Cancer Does Not Meet Overall Survival Endpoint in Phase III Trial

In a phase III trial (ELM-PC 5) reported in the Journal of Clinical Oncology, Fizazi et al found that the addition of the 17,20-lyase inhibitor orteronel to prednisone in patients with metastatic castration-resistant prostate cancer progressing after docetaxel therapy resulted in an overall...

prostate cancer
issues in oncology

Simulation Study Based on ERSPC Data Shows Greatest Cost-Effectiveness With Two to Three PSA Screenings Between 55 and 59 Years of Age

The European Randomized Study of Screening for Prostate Cancer (ERSPC) trial showed a significant 29% prostate cancer mortality reduction with prostate-specific antigen (PSA) screening but a marked negative impact on quality-adjusted life-years gained due to the effect of overdiagnosis on quality...

prostate cancer

No Overall Survival Benefit of Adding Orteronel to Prednisone in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer

In the phase III ELM-PC 4 trial reported in The Lancet Oncology, Saad et al found that the addition of the CYP 17,20 lyase inhibitor orteronel to prednisone did not improve overall survival in chemotherapy-naive patients with metastatic castration-resistant prostate cancer. Improvement in...

prostate cancer

Phase III Trial Shows Improved Survival With Long‑Term Androgen-Deprivation Therapy Plus High-Dose Radiotherapy in Localized Prostate Cancer

In the Spanish phase III DART01/05 GICOR trial reported in Lancet Oncology, Zapatero and colleagues found that long-term androgen-deprivation therapy (ADT) increased biochemical disease-free survival and overall survival vs short-term ADT when combined with high-dose radiotherapy in men with...

Advertisement

Advertisement



Advertisement